spec sheet11 rows
Adapromine is a Soviet-era aminoadamantane, a close relative of amantadine and rimantadine that carries a longer (propyl) side chain. Like the rest of the family it was used as an anti-influenza agent that blocks the viral M2 proton channel, but Russian pharmacology attributed to it extra antiparkinsonian and mild psychostimulant/antidepressant-like activity. The best-characterized data are Russian EEG studies showing cortical activation consistent with a catecholaminergic, stimulant-leaning profile. It is obscure outside the Russian literature and has essentially no modern human trial data.
- Aminoadamantane relative of amantadine with a stimulant lean
- Cortical-activation EEG profile resembling recognized psychostimulants
- Historic dual antiviral and antiparkinsonian reputation
- A window into Soviet-era adamantane pharmacology
- Broad-spectrum influenza A and B activity
- M2 proton-channel antiviral action
- Possible psychostimulant-like CNS effects
- Minimal modern safety data
- Possible stimulation and insomnia (class analogy)
- Antiviral value undercut by M2 resistance
- Caution with other stimulant or dopaminergic drugs
Overview
Adapromine is a Soviet-developed adamantane antiviral, chemically 1-(1-aminopropyl)adamantane (also carrying the research codes JP-62 and MK-3), and an alkyl analogue of rimantadine closely related to amantadine and memantine. The first synthesis of the compound was disclosed by DuPont in patents published in 1967, but it was in the Soviet Union that it was developed and marketed as an anti-influenza agent, where it was valued for a broader spectrum of action than amantadine or rimantadine; unlike those drugs, which act essentially only on influenza A, adapromine is reported to be active against both influenza A and influenza B.
Mechanistically it belongs to the M2 proton-channel inhibitor class, blocking viral uncoating, and it shares cross-resistance with rimantadine and amantadine when M2 transmembrane mutations arise. Alongside its antiviral use it has been studied in Russian pharmacology for psychostimulant-like and antidepressant-like central effects attributed to catecholaminergic activation, placing it among the adamantane cage amines that combine antiviral and CNS activity.
Today adapromine is an obscure compound with a small, aging, and largely Russian-language literature. It has essentially no presence in Western clinical practice, was marketed chiefly in Russia for influenza prophylaxis and treatment, and is best regarded as a historical research chemical of the adamantane series rather than a current mainstream therapeutic.
- Adapromine belongs to the same adamantane 'cage amine' family as amantadine, rimantadine, and memantine, differing only in the side chain hung off the rigid tricyclic core; it is specifically an alkyl analogue of rimantadine [1].
- Unlike amantadine and rimantadine, which act essentially only against influenza A, adapromine is reported to work against both influenza A and influenza B, and related aminopropyl-adamantane conjugates showed activity against herpes simplex, parainfluenza, and respiratory syncytial virus as well [8].
- Influenza A strains resistant to rimantadine, adapromine, and deitiforine were recovered from nature in the USSR and Mongolia starting in the early to mid 1980s, an early real-world signal of adamantane resistance [2][3].
- Beyond its antiviral use, Soviet EEG studies grouped adapromine with psychostimulants such as amphetamine and caffeine, reading its brain-activation profile as evidence of psychostimulant-like and antidepressant-like effects mediated by catecholamines [4][5].
Mechanism
Adapromine (1-(1-aminopropyl)adamantane; C13H23N) is an alkyl analogue of rimantadine within the adamantane family of antivirals, sharing the rigid tricyclic cage of amantadine, rimantadine, and memantine but carrying an aminopropyl side chain in place of amantadine's bare amine or rimantadine's aminoethyl group. Its antiviral action is that of a classic M2 inhibitor. The influenza A M2 protein is a tetrameric proton channel that spans the viral membrane and must conduct protons to acidify the virion interior and permit uncoating; adamantanes lodge in the channel lumen and occlude proton flow, arresting release of the viral genome into the host cell. Studies of influenza variants selected for resistance to rimantadine and the related drug deitiforine showed that these variants become cross-resistant to adapromine and amantadine, and that resistance is accompanied by amino acid substitutions in the hydrophobic transmembrane region of M2 (notably at positions 30 and 31), together with shifts in the optimal pH for hemolysis and elevated transcriptase activity; this locates adapromine's target squarely at the M2 channel and its adjacent pore-lining residues [1].
Adapromine's distinguishing pharmacological feature is a broader antiviral spectrum than amantadine or rimantadine. Where amantadine and rimantadine are active essentially only against influenza A, adapromine is described as effective against both influenza A and influenza B, and work on adamantane-bearing polymer conjugates that included aminopropyl-adamantane demonstrated activity extending to influenza B strains, herpes simplex type 1, parainfluenza types 1 and 3, and respiratory syncytial virus [8]. This wider reach is generally attributed to the more alkyl substituent altering membrane partitioning and target interactions relative to the smaller adamantane amines.
As with the whole adamantane class, the practical value of adapromine's antiviral action was eroded by resistance. Naturally circulating influenza A isolates resistant to rimantadine, adapromine, and deitiforine were recovered in the USSR and Mongolia beginning in the early to mid 1980s; several such strains (for example from Mongolia in 1985 and 1986 and from Moscow in 1988) were antigenically atypical and carried distinctive M and M2 gene features, and the emergence of these resistant strains in the environment was proposed to arise not only from spontaneous mutation and drug selection but possibly from the circulation of vaccine-derived strains [2][3].
Beyond its antiviral role, adapromine has been characterized in Soviet-era neuropharmacology as possessing psychostimulant-like and possibly antidepressant-like central activity. Quantitative EEG (power-spectral) analysis in freely moving rats found that adapromine reduced the amplitude of the dominant peak and dominant theta activity in the and while increasing fast beta-range activity, changes read as cortical and hippocampal activation and interpreted as evidence of an antidepressant and psychostimulant component, plausibly mediated by an effect on brain catecholaminergic (dopaminergic) processes [4]. Comparative EEG studies grouped adapromine with recognized psychostimulants such as amphetamine, caffeine, sydnocarb, and meclofenoxate, noting the shared drop in absolute power across frequency ranges with enhanced fast beta activity [5], and further comparative work examined adapromine alongside the adamantane derivatives midantan (amantadine) and bromantane on rat brain bioelectric activity [6]. These effects are consistent with the known dopaminergic and -modulating actions of the adamantane cage amines, though for adapromine specifically the supporting data are limited and largely preclinical.
receptor fingerprint
Influenza A M2 proton channelpore block (class mechanism)
Brain catecholamine systems (/noradrenaline)activation (EEG-inferred)
receptorantagonist (class inference, not directly shown here)
Mutant M2 (resistant strains)loses activity
Safetyrisks and cautions, not medical advice
Adapromine is an obscure research/antiviral compound with essentially no modern safety characterization outside old Russian literature, so treat it cautiously. By analogy to amantadine-type aminoadamantanes, plausible effects include stimulation, insomnia, and, at higher exposure, the CNS side effects typical of the class; its antiviral usefulness is undercut by the same M2 resistance that ended the adamantanes as flu drugs. Because it appears to raise catecholaminergic tone, caution is warranted with other stimulants or dopaminergic and serotonergic drugs. Not a validated nootropic and not for self-experimentation.
History
Adapromine emerged from the wave of adamantane chemistry that followed the discovery of amantadine's antiviral properties in the 1960s; DuPont disclosed the first synthesis of 1-(1-aminopropyl)adamantane in patents published in 1967, but its therapeutic development took place in the Soviet Union, where it was introduced as an anti-influenza drug of the same family as rimantadine (itself a major Soviet adamantane antiviral) and promoted for activity against both influenza A and B. Through the 1980s and early 1990s Soviet and Russian investigators studied it both as an antiviral, including reports of resistant influenza strains recovered in the USSR and Mongolia, and as a centrally active agent with psychostimulant-like properties, before it faded into obscurity as adamantane resistance spread and newer antivirals appeared.
Reputation
Adapromine is an obscure, largely forgotten Soviet-era adamantane antiviral with a thin and dated evidence base. Almost all of the primary literature is older and in Russian, indexed on PubMed chiefly as English-abstracted journal articles, and there are essentially no modern controlled human trials to draw on; claims of a broader antiviral spectrum than amantadine and of psychostimulant or antidepressant-like CNS effects rest mostly on preclinical EEG work and older Russian clinical reports. It is best treated as a historical curiosity and a research chemical of the adamantane series rather than a validated therapeutic, and its practical antiviral value, like that of the whole adamantane class, was undermined by the spread of M2 resistance in circulating influenza.
Subjective profileweighing the evidence above
Interesting as pharmacological history and little else. The stimulant and antiparkinsonian reputation rests on old Russian literature, the antiviral use was undone by M2 resistance, and there is essentially no modern safety data. Not a validated nootropic and not worth self-experimenting with.
Resources
This entry is here for reference.
Research
- 1987first cited[Interferon and other immunological indices of influenza patients undergoing different methods…
- 2003most recent[Structure and antiviral activity of adamantane-containing polymer preparation].
- 1.[Comparative analysis of effects of adapromine, midantan, and bromantane on the bioelectric activity of the rat brain].
- 2.[A spectral analysis of the effect of adapromine on brain bioelectrical activity].
- 3.[The isolation and study of the properties of current influenza A viruses (H1N1) with a natural resistance to remantadine].
- 4.[Interferon and other immunological indices of influenza patients undergoing different methods of treatment].
- 5.[Comparative quantitative pharmacological-EEG analysis of the effects of psychostimulants].
- 6.[The origin of resistance to chemicals of naturally occurring isolates of influenza A virus].
- 7.[The change in functional activity and primary structure of the M2 protein in variants of the influenza virus resistant to remantadine and deitiforin: common and individual differences from the original strain].
- 8.[Structure and antiviral activity of adamantane-containing polymer preparation].
8 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
How is adapromine related to amantadine and rimantadine?
They are all aminoadamantanes built on the same cage; adapromine carries a longer propyl side chain. That family kinship is why it shares the anti-influenza M2 mechanism and the same resistance problem.
Is it a stimulant?
Mildly, based on rat EEG studies that place it alongside amphetamine and caffeine by their shared cortical-activation signature. That is animal electrophysiology, not proven human stimulant effect.
Does it still work against the flu?
Not reliably. Soviet studies already found influenza A strains cross-resistant to adapromine and remantadine via M2 mutations, the same escape that made the adamantanes obsolete for seasonal flu.
Is the dopamine claim solid?
It is an inference. The EEG papers attribute its effects to catecholaminergic (dopamine/noradrenaline) systems and it is class-related to dopaminergic amantadine, but direct receptor data in these reports are limited.
Adverse effects
- Minimal modern safety data
- Possible stimulation and insomnia (class analogy)
- Antiviral value undercut by M2 resistance
- Caution with other stimulant or dopaminergic drugs